CRIO, a leading eSource provider, has secured a substantial investment from The Riverside Company. This funding will accelerate the expansion of CRIO’s eClinical platform, offering enhanced value to clinical research sites, biopharmaceutical companies, and CROs.

CRIO’s platform integrates eSource, clinical trial management systems, eConsent, electronic data capture, remote monitoring, and source data verification. It streamlines research at the site level, reduces costs, increases trial speed, and improves data quality.

CRIO’s innovative direct data capture solution challenges traditional data capture methods and improves research site workflows. The platform reduces administrative burdens and enables faster and more efficient clinical trials.

The investment empowers CRIO to expand its capabilities and introduce new functionalities, transforming clinical trial data capture and management. It will accelerate product development and international expansion and enhance customer support.

CRIO’s mission is to provide a comprehensive software platform that optimizes clinical trials for quality, speed, and patient-centricity. The investment from The Riverside Company supports this vision and will enable CRIO to continue delivering on its promise to its clients.

The Riverside Company’s track record of success with similar companies and its industry expertise is expected to create significant value for CRIO’s clients. The investment will enable CRIO to enhance its offerings further and expand its global reach, ultimately making life-changing therapies more accessible to patients.

Source link:

author avatar
Ferry Darma
Ferry Darma is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.